Ondine appoints Spanish distributer for Steriwave

 21 November 2022

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Ondine appoints Spanish distributer for Steriwave

Canadian life sciences company Ondine Biomedical has appointed leading medical device distributer, Distrauma Medical SL, to distribute its Steriwave ™ nasal photodisinfection in Spain. Distrauma, a national medical device supplier focusing on surgical equipment for hospitals, was founded in 1994 and is headquartered in Barcelona, Spain. The primary application for Steriwave nasal photodisinfection is nasal decolonization for the prevention of healthcare-associated infections, including surgical site infections.

Steriwave can eliminate nasal bacteria, viruses, and fungi with a simple, 5-minute, non-antibiotic treatment. The two-step process involves the application of a proprietary light-activated agent to each nostril using a nasal swab, followed by illumination of the area with a specific wavelength of laser light. The light activates the photodynamic agent, causing an oxidative burst that destroys all types of pathogens. A key benefit of this approach is that pathogens do not develop resistance to the therapy.

Steriwave has a CE mark for use in the EU and is approved in Canada, the UK, and several other countries.

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.